FANAPT (iloperidone)

FANAPT (iloperidone) 

Self-Administration - oral

Diagnosis considered for coverage:

• Schizophrenia - Indicated for the treatment of adults with schizophrenia.

Coverage Criteria:

For diagnosis of Schizophrenia:

• Dose does not exceed 12 mg twice daily (24 mg/day); AND

• Inadequate response, intolerance, or contraindication to two of the following:

  • Aripiprazole
  • Olanzapine
  • Quetiapine IR/ER
  • Risperidone
  • Clozapine
  • Ziprasidone
  • Paliperidone
  • Asenapine

Coverage Duration:

• Initial: 1 year

Authorization is not covered for the following:

• The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:

• Drug Interactions:
  • The dose of Fanapt should be reduced in patients who co-administered a strong CYP2D6 or CYP3A4 inhibitor

Policy Updates:

• 02/15/2022 – New policy approved by P&T

References:

1. Fanapt prescribing information. Vanda Pharmaceuticals, Inc. Washington, D.C. January 2016.